An intestinal chip model takes research of fungal infections to a new level

Successful cooperation between science, clinic and start-up

25-Mar-2024 - The Jena-based biotech company Dynamic42 has developed an intestine-on-chip candidiasis model that allows for the quantification of the infection process. By combining microbiological and image-based analyses, the pathogen-host interactions can be analyzed much more precisely than is possible ...

Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I

04-Jan-2024 - Evotec SE and Owkin, a French-American techbio startup announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation (“I&I”). The collaboration brings together highly complementary platforms and expertise to accurately select targets, discover and ...

LDC and JT team up for the discovery of new therapies

12-Oct-2023 - The Lead Discovery Center GmbH (LDC) and Japan Tobacco Inc. (JT) have closed a collaboration agreement to discover new first-in-class therapeutic approaches, focusing around novel chemical entities for the treatment of various diseases with significant unmet medical need. Over a period of up to ...

SAS accelerates delivery of novel medicines using AI and analytics

Cooperation with AstraZeneca for more innovation in clinical research

12-Oct-2023 - SAS, a leader in AI and analytics, is helping to revolutionize the use of clinical trial data so new medicines can be delivered to patients faster than before. After a thorough evaluation, SAS has been chosen by global biopharmaceutical company AstraZeneca to help increase efficiency and drive ...

Use of Artificial Intelligence in Drug Development

WACKER, CordenPharma, LMU and HU Berlin Train Machine Learning Algorithm for the Formulation of RNA Actives

03-Apr-2023 - Together with Munich’s Ludwig Maximilian University (LMU) and the Humboldt University of Berlin (HU Berlin), Wacker Chemie AG and CordenPharma International GmbH have launched a project to accelerate the development of RNA-based drugs. The aim is to develop a new generation of lipid nanoparticles ...

As easy as Googling - AI finds the right substances

Chemspace and PharmAI collaborate to make the world's largest online catalog of small molecules and biologics even more user-friendly

07-Oct-2022 - Searching for the right chemical compounds is going to be as easy as Googling. That’s the reason behind the Dresden-based start-up PharmAI and the Ukrainian company Chemspace now signing a collaboration agreement. While the Kyiv-based company is the provider of the world's most comprehensive ...

Evotec receives € 7.5 m grant for development of COVID-19 therapeutic

Evotec is developing a highly potent immunomodulatory molecule that holds the potential to reduce the risk of difficult disease progression and hospitalisation

04-Jan-2022 - Evotec SE announced that the Company has been selected by the German Federal Ministry of Education and Research (“BMBF”) to receive a grant for the development of EVT075, a potential first-in-class immunomodulatory therapy against COVID 19. Evotec is one of three companies receiving a highly ...

Development of targeted SARS-CoV-2 antivirals

Eisbach Bio receives 6.7 million Euros grant from the Bavarian Government

10-Nov-2021 - Eisbach Bio, a biotechnology startup targeting the molecular machines that drive human disease, already received funding of 8 million euros from the German Federal Ministry of Education and Research (BMBF) in July 2021. At the end of October 2021, the start-up announces another financial support ...

How much does it really cost to develop a new drug?

18-Aug-2021 - Along with direct investments, the high risk of failure and the considerable time to market all determine the costs of drug development. Yet how much does it really cost to develop a new drug? Published estimates arrive at very different results. Scientists from the German Cancer Research Center ...

Start-up raises hope in the fight against acute and chronic liver diseases

The biotech company HepaRegeniX, founded in 2017, starts clinical testing of the tolerability of its developed drug in volunteers.

11-Aug-2021 - The Tübingen-based start-up HepaRegeniX recently began a Phase I clinical trial to test the tolerability of a novel drug against liver disease in healthy volunteers. The drug is a so-called MKK4 inhibitor, which, when administered, curbs the activity of the kinase MKK4. Preclinical studies have ...